CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating

Positive
AI Analysis

Summary

RBC Capital increased its price target for Ultragenyx Pharmaceutical to $40 from $35 while maintaining an Outperform rating.

Importance:2/10
Sentiment:
0.30
price_targetanalyst_ratingequity_research
Related Companies

Read the original article

Published by yahoo_finance on July 7, 2026 11:51 AM

Read Original